Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
International Urogynecology Journal
Erschienen in: International Urogynecology Journal 7/2013

01.07.2013 | Review Article

Botulinum toxin for conditions of the female pelvis

verfasst von: Dominique El-Khawand, Salim Wehbe, Kristene Whitmore

Erschienen in: International Urogynecology Journal | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

Botulinum toxin has recently been approved by the Food and Drug Administration (FDA) for the treatment of urinary incontinence associated with neurogenic detrusor overactivity. However, it has also been used off-label for a multitude of other conditions in the female pelvis, including urological, gynecological, and colorectal. This article reviews the most recent data regarding its efficacy and safety, and administration techniques for those conditions.

Methods

A literature review of the most relevant reports published between 1985 and 2012.

Results

Urinary incontinence related to neurogenic detrusor overactivity is currently the only approved indication in the female pelvis. Other supported off-label uses include: idiopathic detrusor overactivity, interstitial cystitis/bladder pain syndrome, detrusor sphincter dyssynergia, high-tone pelvic floor dysfunction, anal fissure, anismus, and functional anal pain.

Conclusions

Botulinum toxin may effectively and safely be used in many conditions of the female pelvis. More high quality research is needed to better clarify its role in the therapeutic algorithm for those indications.
Literatur
1.
Hanchanale VS, Rao AR, Martin FL, Matanhelia SS (2010) The unusual history and the urological applications of botulinum neurotoxin. Urol Int 85(2):125–130PubMedCrossRef
2.
Leong RK, De Wachter SG, van Kerrebroeck PE (2010) Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review. Urol Int 84(3):245–253PubMedCrossRef
3.
Brashear A (2008) Clinical comparisons of botulinum neurotoxin formulations. Neurologist 14(5):289–298PubMedCrossRef
4.
Dressler D, Benecke R (2007) Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 29(23):1761–1768PubMedCrossRef
5.
Cruz F, Herschorn S, Aliotta P et al (2011) Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 60(4):742–750PubMedCrossRef
6.
Krhut J, Samal V, Nemec D, Zvara P (2012) Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study. Spinal Cord 50(12):904–907PubMedCrossRef
7.
Abdel-Meguid TA (2010) Botulinum toxin-A injections into neurogenic overactive bladder–to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol 184(6):2423–2428PubMedCrossRef
8.
Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D (2011) Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev (12):CD005493
9.
Dmochowski R, Chapple C, Nitti VW et al (2010) Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 184(6):2416–2422PubMedCrossRef
10.
Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P (2011) Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 30(4):556–562PubMedCrossRef
11.
Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A (2012) Repeated botulinum toxin type A Injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol 61(4):834–839PubMedCrossRef
12.
Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D et al (2012) Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 62(3):507–514PubMedCrossRef
13.
Kuo HC (2011) Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 30(7):1242–1248PubMed
14.
Manecksha RP, Cullen IM, Ahmad S et al (2012) Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol 61(5):928–935PubMedCrossRef
15.
Kuo HC (2007) Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 178(4 Pt 1):1359–1363PubMedCrossRef
16.
Tirumuru S, Al-Kurdi D, Latthe P (2010) Intravesical botulinum toxin A injections in the treatment of painful bladder syndrome/interstitial cystitis: a systematic review. Int Urogynecol J 21(10):1285–1300PubMedCrossRef
17.
Kuo HC, Chancellor MB (2009) Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int 104(5):657–661PubMedCrossRef
18.
Mangera A, Andersson KE, Apostolidis A et al (2011) Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 60(4):784–795PubMedCrossRef
19.
Gallien P, Reymann JM, Amarenco G, Nicolas B, de Seze M, Bellissant E (2005) Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 76(12):1670–1676PubMedCrossRef
20.
Rao A, Abbott J (2009) Using botulinum toxin for pelvic indications in women. Aust N Z J Obstet Gynaecol 49(4):352–357PubMedCrossRef
21.
Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG (2006) Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 108(4):915–923PubMedCrossRef
22.
Goldstein AT, Burrows LJ, Kellogg-Spadt S (2011) Intralevator injection of botulinum toxin for the treatment of hypertonic pelvic floor muscle dysfunction and vestibulodynia. J Sex Med 8(5):1287–1290PubMedCrossRef
23.
Bertolasi L, Frasson E, Cappelletti JY, Vicentini S, Bordignon M, Graziottin A (2009) Botulinum neurotoxin type A injections for vaginismus secondary to vulvar vestibulitis syndrome. Obstet Gynecol 114(5):1008–1016PubMedCrossRef
24.
Haefner HK (2007) Report of the International Society for the Study of Vulvovaginal Disease terminology and classification of vulvodynia. J Low Genit Tract Dis 11(1):48–49PubMedCrossRef
25.
Andrews JC (2011) Vulvodynia interventions—systematic review and evidence grading. Obstet Gynecol Surv 66(5):299–315PubMedCrossRef
26.
Petersen CD, Giraldi A, Lundvall L, Kristensen E (2009) Botulinum toxin type A-a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J Sex Med 6(9):2523–2537PubMedCrossRef
27.
Yiannakopoulou E (2012) Botulinum toxin and anal fissure: efficacy and safety systematic review. Int J Colorectal Dis 27(1):1–9PubMedCrossRef
28.
Jost WH, Schimrigk K (1993) Use of botulinum toxin in anal fissure. Dis Colon Rectum 36(10):974PubMedCrossRef
29.
Nyam DC, Pemberton JH (1999) Long-term results of lateral internal sphincterotomy for chronic anal fissure with particular reference to incidence of fecal incontinence. Dis Colon Rectum 42(10):1306–1310PubMedCrossRef
30.
Valizadeh N, Jalaly NY, Hassanzadeh M et al (2012) Botulinum toxin injection versus lateral internal sphincterotomy for the treatment of chronic anal fissure: randomized prospective controlled trial. Langenbecks Arch Surg 397(7):1093–1098PubMedCrossRef
31.
Sierra F (2005) Evidence-Based Medicine (EBM) in practice: applying number needed to treat and number needed to harm. Am J Gastroenterol 100(8):1661–1663PubMedCrossRef
32.
Mentes BB, Irkorucu O, Akin M, Leventoglu S, Tatlicioglu E (2003) Comparison of botulinum toxin injection and lateral internal sphincterotomy for the treatment of chronic anal fissure. Dis Colon Rectum 46(2):232–237PubMedCrossRef
33.
Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Gui D, Albanese A (2000) Influence of botulinum toxin site of injections on healing rate in patients with chronic anal fissure. Am J Surg 179(1):46–50PubMedCrossRef
34.
Brisinda G, Cadeddu F, Brandara F, Marniga G, Maria G (2007) Randomized clinical trial comparing botulinum toxin injections with 0.2 per cent nitroglycerin ointment for chronic anal fissure. Br J Surg 94(2):162–167PubMedCrossRef
35.
Brisinda G, Albanese A, Cadeddu F et al (2004) Botulinum neurotoxin to treat chronic anal fissure: results of a randomized “Botox vs. Dysport” controlled trial. Aliment Pharmacol Ther 19(6):695–701PubMedCrossRef
36.
Preston DM, Lennard-Jones JE (1985) Anismus in chronic constipation. Dig Dis Sci 30(5):413–418PubMedCrossRef
37.
Hompes R, Harmston C, Wijffels N, Jones OM, Cunningham C, Lindsey I (2012) Excellent response rate of anismus to botulinum toxin if rectal prolapse misdiagnosed as anismus (‘pseudoanismus’) is excluded. Colorectal Dis 14(2):224–230PubMedCrossRef
38.
Faried M, El Nakeeb A, Youssef M, Omar W, El Monem HA (2010) Comparative study between surgical and non-surgical treatment of anismus in patients with symptoms of obstructed defecation: a prospective randomized study. J Gastrointest Surg 14(8):1235–1243PubMedCrossRef
39.
Rao SS, Tuteja AK, Vellema T, Kempf J, Stessman M (2004) Dyssynergic defecation: demographics, symptoms, stool patterns, and quality of life. J Clin Gastroenterol 38(8):680–685PubMedCrossRef
40.
Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ 3rd (1993) Functional constipation and outlet delay: a population-based study. Gastroenterology 105(3):781–790PubMed
41.
DiPalma JA (2004) Current treatment options for chronic constipation. Rev Gastroenterol Disord 4 [Suppl 2]:S34–S42PubMed
42.
Park UC, Choi SK, Piccirillo MF, Verzaro R, Wexner SD (1996) Patterns of anismus and the relation to biofeedback therapy. Dis Colon Rectum 39(7):768–773PubMedCrossRef
43.
Farid M, El Monem HA, Omar W et al (2009) Comparative study between biofeedback retraining and botulinum neurotoxin in the treatment of anismus patients. Int J Colorectal Dis 24(1):115–120PubMedCrossRef
44.
Joo JS, Agachan F, Wolff B, Nogueras JJ, Wexner SD (1996) Initial North American experience with botulinum toxin type A for treatment of anismus. Dis Colon Rectum 39(10):1107–1111PubMedCrossRef
45.
Shafik A, El-Sibai O (1998) Botulin toxin in the treatment of nonrelaxing puborectalis syndrome. Dig Surg 15(4):347–351PubMedCrossRef
46.
Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Albanese A (2000) Botulinum toxin in the treatment of outlet obstruction constipation caused by puborectalis syndrome. Dis Colon Rectum 43(3):376–380PubMedCrossRef
47.
Ron Y, Avni Y, Lukovetski A et al (2001) Botulinum toxin type-A in therapy of patients with anismus. Dis Colon Rectum 44(12):1821–1826PubMedCrossRef
48.
Maria G, Cadeddu F, Brandara F, Marniga G, Brisinda G (2006) Experience with type A botulinum toxin for treatment of outlet-type constipation. Am J Gastroenterol 101(11):2570–2575PubMedCrossRef
49.
Hollingshead JR, Maeda Y, Brown TJ, Warusavitarne J, Vaizey CJ (2011) Long-term outcome of the use of botulinum toxin injection for functional anal pain. Colorectal Dis 13(9):e293–e296PubMedCrossRef
50.
Christiansen J, Bruun E, Skjoldbye B, Hagen K (2001) Chronic idiopathic anal pain: analysis of ultrasonography, pathology, and treatment. Dis Colon Rectum 44(5):661–665PubMedCrossRef
51.
Hallan RI, Williams NS, Melling J, Waldron DJ, Womack NR, Morrison JF (1988) Treatment of anismus in intractable constipation with botulinum A toxin. Lancet 2(8613):714–717PubMedCrossRef
52.
Shepherd JP, Lowder JL, Leng WW, Smith KJ (2011) InterStim sacral neuromodulation and botox botulinum-a toxin intradetrusor injections for refractory urge urinary incontinence: a decision analysis comparing outcomes including efficacy and complications. Female Pelvic Med Reconstr Surg 17(4):199–203PubMedCrossRef
53.
Siddiqui NY, Amundsen CL, Visco AG, Myers ER, Wu JM (2009) Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol 182(6):2799–2804PubMedCrossRef
54.
Leong RK, de Wachter SG, Joore MA, van Kerrebroeck PE (2011) Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int 108(4):558–564PubMedCrossRef
55.
Hanno PM, Burks DA, Clemens JQ et al (2011) AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol 185(6):2162–2170PubMedCrossRef
Metadaten
Titel
Botulinum toxin for conditions of the female pelvis
verfasst von
Dominique El-Khawand
Salim Wehbe
Kristene Whitmore
Publikationsdatum
01.07.2013
Verlag
Springer London
Erschienen in
International Urogynecology Journal / Ausgabe 7/2013
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-012-2035-1

Weitere Artikel der Ausgabe 7/2013

International Urogynecology Journal 7/2013 Zur Ausgabe

Original Article

The PISQ-IR: considerations in scale scoring and development

Original Article

Patient reported outcome measures in women undergoing surgery for urinary incontinence and pelvic organ prolapse in Denmark, 2006–2011

Case Report

Surgical repair of bilateral levator ani muscles with ultrasound guidance

Original Article

Lack of effect of concomitant stage II cystocele repair on lower urinary tract symptoms and surgical outcome after tension-free vaginal tape procedure: randomized controlled trial

Editorial

The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR)

Original Article

Randomized trial of a comparison of rehabilitation or drug therapy for urgency urinary incontinence: 1-year follow-up

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise